Top Page
Medicenna Therapeutics Corp
(TSX:MDNA)
Medicenna Therapeutics Corp (MDNA) vs. iShares MSCI Canada ETF (EWC)
Medicenna Therapeutics Corp Business Overview & Revenue Model
Medicenna Therapeutics Corp Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -42.00K | -55.00K | -5.00K | -5.00K | -38.00K | -40.00K |
| EBITDA | -21.15M | -12.97M | -16.30M | -18.67M | -22.54M | -17.25M |
| Net Income | -13.81M | -11.80M | 1.55M | -25.47M | -22.65M | -17.18M |
Balance Sheet | ||||||
| Total Assets | 18.04M | 28.38M | 36.45M | 19.13M | 23.46M | 42.25M |
| Cash, Cash Equivalents and Short-Term Investments | 15.75M | 24.84M | 33.60M | 16.98M | 20.54M | 40.38M |
| Total Debt | 149.00K | 168.00K | 0.00 | 0.00 | 0.00 | 34.00K |
| Total Liabilities | 7.80M | 9.29M | 6.96M | 13.94M | 2.62M | 4.11M |
| Stockholders Equity | 10.24M | 19.09M | 29.49M | 5.19M | 20.84M | 38.15M |
Cash Flow | ||||||
| Free Cash Flow | -17.03M | -16.52M | -12.66M | -16.26M | -23.58M | -15.31M |
| Operating Cash Flow | -17.03M | -16.49M | -12.66M | -16.26M | -23.58M | -15.31M |
| Investing Cash Flow | 0.00 | -33.00K | -13.05M | 0.00 | 10.05M | 5.01M |
| Financing Cash Flow | 1.91M | 23.49M | 24.76M | 0.00 | 3.88M | 18.26M |
Medicenna Therapeutics Corp Technical Analysis
Medicenna Therapeutics Corp Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$47.71M | 23.17 | 7.07% | ― | 5.29% | -29.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $176.23M | -4.80 | -89.10% | ― | ― | 27.53% | |
44 Neutral | C$64.60M | -5.48 | -91.21% | ― | ― | 54.74% | |
26 Underperform | C$90.57M | -37.33 | ― | ― | ― | 10.49% |
Medicenna Therapeutics Corp Corporate Events
Medicenna reported updated clinical data for its lead IL-2 super agonist MDNA11 from the ongoing Phase 1/2 ABILITY-1 trial, showing encouraging objective response rates in heavily pretreated cancer patients, particularly in the second- and third-line setting and following failure of immune checkpoint inhibitors. Based on these results, the company plans to complete ABILITY-1 enrollment and prepare a registrational trial in second-/third-line melanoma and other selected tumors post-checkpoint failure, while also supporting the NEO-CYT investigator-sponsored study that will test MDNA11 as front-line therapy in resectable advanced cutaneous melanoma starting in the first half of 2026. Medicenna also highlighted preclinical safety data for MDNA113, a conditionally activated bifunctional anti-PD-1–IL-2 superkine that could allow dosing comparable to current anti-PD-1 drugs, with an investigational new drug filing and first-in-human trial targeted for the second half of 2026. The company intends to showcase additional data on its bizaxofusp program at an upcoming glioblastoma conference and stated that its cash runway now extends into the third quarter of 2026, supporting continued advancement of its superkine platform and reinforcing its bid to establish a leadership position in next-generation immunotherapies for difficult-to-treat cancers.
The most recent analyst rating on (TSE:MDNA) stock is a Hold with a C$0.91 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics outlined a potentially pivotal 2026 as it advances its Superkine immunotherapy pipeline, led by IL-2 super agonist MDNA11 and conditionally activated bifunctional anti-PD1–IL-2 candidate MDNA113. Updated data from the Phase 1/2 ABILITY-1 trial show strong monotherapy activity for MDNA11 in heavily pretreated patients, with overall response rates of 50% in second- and third-line (2L/3L) settings and 42% when used immediately after checkpoint inhibitor failure in select expansion cohorts, and meaningful response rates across 18 cancer types; similar efficacy trends were observed in combination with pembrolizumab. On the back of these results, the company plans to complete ABILITY-1 enrollment and prepare a registrational trial in 2L/3L melanoma and other tumors post-ICI failure, while an externally sponsored NEO-CYT study will move MDNA11 into front-line therapy for resectable advanced cutaneous melanoma starting in the first half of 2026. Meanwhile, preclinical data for MDNA113 in non-human primates support dosing comparable to approved anti-PD-1 therapies, with an IND filing and first-in-human trial targeted for the second half of 2026, bolstering Medicenna’s strategy to position its IL-2-based platform as best-in-class in a competitive immuno-oncology landscape. The company also plans multiple bizaxofusp data presentations at a major glioblastoma meeting and reports a cash runway extending into the third quarter of 2026, providing financial visibility to support these clinical milestones.
The most recent analyst rating on (TSE:MDNA) stock is a Hold with a C$0.91 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics Corp announced updated clinical trial results for MDNA11 at the ESMO-IO Congress 2025, highlighting its durable anti-tumor activity in advanced solid tumors, particularly in immune checkpoint-resistant cancers. The trial demonstrated promising objective response rates and disease control rates in various cancer types, indicating MDNA11’s potential efficacy in earlier lines of treatment. The results suggest meaningful therapeutic potential, with a manageable safety profile, reinforcing MDNA11’s positioning as a promising candidate in the oncology market.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics announced a live webinar to discuss updated clinical data from their ABILITY-1 Phase 1/2 Study on MDNA11, both as a monotherapy and in combination with pembrolizumab. The webinar, featuring presentations from the company’s executive and scientific advisory team, aims to provide insights into the study’s findings and implications for Medicenna’s operations and industry positioning. This event underscores the company’s commitment to advancing its pipeline and engaging with stakeholders through transparent communication.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics Corp announced its second quarter fiscal 2026 financial results and provided a corporate update, highlighting significant advancements in its Superkine programs. The company is set to present updated clinical data for MDNA11 at the ESMO Immuno-Oncology Congress and is launching a new clinical trial in Italy to evaluate MDNA11 in combination with checkpoint inhibitors for melanoma. Additionally, Medicenna is advancing its MDNA113 bispecific program and has strengthened its patent portfolio, which underscores its commitment to pioneering innovative therapies in oncology.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics Corp has announced a collaboration with Fondazione Melanoma Onlus to conduct the NEO-CYT trial, which will evaluate MDNA11, a next-generation IL-2 Superkine, as a neoadjuvant immunotherapy for high-risk, surgically resectable Stage III melanoma. This trial aims to assess the potential of MDNA11 in combination with checkpoint inhibitors to improve pathologic responses and potentially enhance curative outcomes after surgery. The study represents a significant step in the clinical development of MDNA11, potentially expanding its use in earlier-stage melanoma and broadening its market reach.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics Corp announced that updated clinical data from their Phase 1/2 ABILITY-1 Study on MDNA11 will be presented at the European Society for Medical Oncology Immuno-Oncology Congress 2025. This presentation will highlight the potential of MDNA11 as a monotherapy and in combination with pembrolizumab for treating advanced solid tumors, potentially enhancing Medicenna’s position in the immunotherapy market and offering new hope for stakeholders in cancer treatment.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Medicenna Therapeutics Corp announced its participation in several upcoming conferences, including the Planet MicroCap Showcase, BIO-Europe 2025, and the Oppenheimer Miami Oncology Summit. These events will allow the company to present its innovative therapies and engage with potential partners and investors, highlighting its pipeline of Superkines and ongoing clinical trials. This participation is expected to enhance Medicenna’s industry positioning and provide opportunities for strategic partnerships.
The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.